Joris A. Van Der Post
Amsterdam, NH 1105AZ, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 106 publications
Balancing harm and benefit for induction of labor at 41 weeks: Slow acting is the problem.
Journal: Acta obstetricia et gynecologica Scandinavica
Published: May 19, 2025
Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial.
Journal: Lancet (London, England)
Published: January 20, 2025
Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.
Journal: JAMA
Published: January 06, 2025
"Hypertension in Pregnancy Intervention Trial At Term" and "Disproportionate Intrauterine Growth Intervention Trial At Term" Studies.
Journal: Clinical obstetrics and gynecology
Published: April 10, 2024
Prevotella timonensis Bacteria Associated With Vaginal Dysbiosis Enhance Human Immunodeficiency Virus Type 1 Susceptibility Of Vaginal CD4+ T Cells.
Journal: The Journal of infectious diseases
Published: October 26, 2023
Offspring school performance at age 12 after induction of labor vs non-intervention at term: A linked cohort study.
Journal: Acta obstetricia et gynecologica Scandinavica
Published: October 08, 2022
Elective induction of labour and expectant management in late-term pregnancy: A prospective cohort study alongside the INDEX randomised controlled trial.
Journal: European journal of obstetrics & gynecology and reproductive biology: X
Published: March 25, 2022
Does induction of labor at 41 weeks (early, mid or late) improve birth outcomes in low-risk pregnancy? A nationwide propensity score-matched study.
Journal: Acta obstetricia et gynecologica Scandinavica
Published: March 23, 2022
Risk factors for spontaneous preterm birth among healthy nulliparous pregnant women in the Netherlands, a prospective cohort study.
Journal: Health science reports
Published: January 28, 2022
Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The lancet. Diabetes & endocrinology
Published: November 29, 2021
Last Updated: 09/26/2026